The Alexander Group’s Post

Learn how utilizing robust data and analytics platforms, such as TriNetX enables companies like Sanofi to assess patient population and optimize their cohorts for diverse representation. Read the full article: https://ow.ly/XxtP30szIr3 Access our diversity resources for better patient outcomes: ow.ly/lOVq30szIq8

Learn how utilizing robust data and analytics platforms, such as TriNetX enables companies like Sanofi to assess patient population and optimize their cohorts for diverse representation. Read the full article: https://ow.ly/x16W30szJmZ Access our diversity resources for better patient outcomes: ow.ly/lOVq30szIq8

Learn how utilizing robust data and analytics platforms, such as TriNetX enables companies like Sanofi to assess patient population and optimize their cohorts for diverse representation. Read the full article: https://ow.ly/EEMr30szNZ5 Access our diversity resources for better patient outcomes: ow.ly/lOVq30szIq8

Learn how utilizing robust data and analytics platforms, such as TriNetX enables companies like Sanofi to assess patient population and optimize their cohorts for diverse representation. Read the full article: https://ow.ly/wpAc30szJlG Access our diversity resources for better patient outcomes: ow.ly/lOVq30szIq8

Learn how utilizing robust data and analytics platforms, such as TriNetX enables companies like Sanofi to assess patient population and optimize their cohorts for diverse representation. Read the full article: https://ow.ly/xhap30szMr4 Access our diversity resources for better patient outcomes: ow.ly/lOVq30szIq8

Are you struggling to navigate complex patient journeys within the diagnostic landscape? Do you have all the insights and recommendations to build your next successful commercialization strategy? The challenge of limited insight into the diagnostic landscape for precision medicine is a stark reality, potentially resulting in the loss of up to 49% of eligible patient. At Diaceutics, we understand the need for in-depth data driven insights to help navigate complex patient journeys and maximize therapy adoption. Our team of precision medicine experts empower you to confidently overcome barriers to commercial success through providing an in-depth qualitative diagnostic market analysis. With over 160 successful Market Landscapes delivered to the top 40 pharma and biotech companies globally, we have been the trusted partner for closing patient leakage gaps within commercial strategy, driving test adoption and treatment activation. Transform patient outcomes with Diaceutics Market Landscape, enabling patients to receive the right test and treatment for their specific disease. Find out more about Diacautics Market Landscape: https://lnkd.in/ebu5RtdW #BetterTestingBetterTreatment #precisionmedicine 

ONCOLOGY OUTLOOK: John Hennessy files his final report from AVBCC 2023. Alternative Sites of Care “It became very clear that employers are interested in exploring alternative sites of care as the cost of oncology is becoming the most important expense line in their employee benefits health plan, surpassing musculoskeletal disease in the last year or so,” Hennessy said. “It’s also clear that entrepreneurs are looking at developing lower cost solutions, including freestanding infusion centers, and home infusion capabilities. These solutions will absolutely be disruptive to the traditional models of delivering oncology care.” Patient Support Services They need to be broadened, Hennessy said, “as gaps in care become more evident. We have been aware for some time that financial assistance is needed as many patients present for a new therapy while carrying existing medical debt. It is also becoming more clear that patient logistics creates barriers to access, and pricing and practice support systems will need to step up to fill that need.” Cell and Gene Therapy There were a number of discussions at AVBCC about the promise of cell and gene therapy, Hennessy said, “while at the same time creating economic chaos for payers, particularly self-funded employers. This is again a place where we may find entrepreneurial solutions, which can help narrow the gap for all parties.” Learn more: https://lnkd.in/gZDcFNne #oncology #marketaccess #pharma #biotech #cancercare

🔍 Webinar Alert! 🔍 Join us for an insightful webinar titled "Beyond the Obvious: Identifying Unmet Needs for HCPs, Patients & Success" on June 20th, 2024, at 12:00 PM EST. In this session, we'll dive into the best research methods to identify both rational and emotional benefits not sufficiently met by competitors. Don't miss out on these key takeaways: ✨ Dominate Your Market: Develop winning strategies by exploiting competitor weaknesses. ✨ Future-Proof Your Growth: Adapt strategies to market shifts and patient needs. ✨ Unlock Hidden Demand: Unearth the emotional needs driving HCP & patient decisions. ✨ Revolutionize Treatment: Identify critical gaps current therapies leave behind. ✨ Craft Messages that Resonate: Learn to stand out from the crowd with powerful differentiation. 👉 Register Now: https://lnkd.in/eNu8Mgqm #Webinar #HealthcareConsulting #MarketStrategy #HCPInsights #Healthcare #ZoomRx #Biopharma #Lifesciences

ESMO - European Society for Medical Oncology 2023: Key Updates & Insights The results from the Phase III trial CheckMate 77T indicated that neoadjuvant OPDIVO combined with chemotherapy reduced the risk of disease recurrence, progression, or death by 42% in patients with resectable stage IIA to IIIB NSCLC. Furthermore, pathologic response improved, and the safety profile remained stable. Explore More: https://lnkd.in/d66peyvD #ESMO #ESMOConference #ESMOConferenceCoverage #partnering #healthcareconsulting #networking #Innovation #PharmaExperts #healthcare #lifesciences #biotechnology #lifescience #marketresearch #marketanalysis #markettrends #marketforecast #health #medical #healthcareindustry #consulting #healthcareconsulting #seminar #conference #healthcareconference #healthcareevents #events #nonsmallcelllungcancer #NSCLC #lungcancer

Are you in the process of designing your drug launch strategy? Are you looking for real-world data-driven insights on the current patient diagnostic/testing landscape to inform your commercial strategy? Diaceutics Market Landscape provides a deep analysis powered by real-world data insights, leveraging our DXRX Lab Network. Gain a deep understanding of the testing market empowering you to confidently overcome the barriers to commercial success for your precision medicine diagnostic. We have identified 6 key barriers to diagnostic testing that undermine the success of your commercialization strategy. Discover the impact of overlooking these barriers below. Find out more here: https://lnkd.in/ebu5RtdW #BetterTestingBetterTreatment #precisionmedicine